Luxhxvrmgierd8imtoqs

Customer studies: ColdZyme users fight colds early and actively

News   •   Apr 27, 2016 12:15 GMT

Media no image

Information about Enzymatica’s new rights issue

News   •   Apr 20, 2016 13:05 GMT

Today Enzymatica has published the prospectus for the new rights issue with pre-emptive rights for the company’s shareholders. To read more about the subscription of shares – see under “Investors” and “New rights issue April 2016” at the company’s web site. Here you will find a brief description of the rights issue (short version of the prospectus) and how one subscribes for shares and application form. The entire prospectus in Swedish is also available.

For more information, please contact:

Carl-Johan Wachtmeister, deputy communication officer Enzymatica

Tel: 0701-88 50 21 | E-post: carl-johan.wachtmeister@enzymatica.com

Important information

The information in this News does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Enzymatica AB (publ). Any invitation to the persons concerned to subscribe for shares in Enzymatica AB (publ) will only be made through the prospectus that Enzymatica AB (publ) estimates to publish on or about 20 April 2016.

Read more »
Media no image

Frequently asked questions and answers about Enzymatica's acquisition of Zymetech

News   •   Jan 28, 2016 07:24 GMT

Why is Enzymatica purchasing Icelandic company Zymetech?

The acquisition of Zymetech aims to accelerate our expansion and reduce the company’s risks of competition. It makes Enzymatica a stronger and more attractive partner in the context of businessand on the capital market.

How does Enzymatica benefit from the acquisition of Zymetech?

The acquisition will give Enzymatica control over the entire production chain, we will own patent protection for our products on several key markets and we will substantially reduce the risk of competition by acquiring global exclusive rights to the deep-sea enzyme. In addition, Zymetech brings expertise in enzyme and formulation technology to the table, which is conducive to the development of new products. When combined with the other improvements we have made to the company over the past year, such as in terms of quality and regulations, this gives us the solid foundation required to make our planned geographic expansion a reality.

What are the details of the transaction?

Enzymatica AB (publ) (”Enzymatica”) has signed an agreement to acquire the shares of Zymetech ehf. The purchase price consists of 20,9 million new shares and 4 million new warrants in Enzymatica, and the acquisition is thus planned to be completed via a non-cash issue of shares in Enzymatica offered to Zymetech’s shareholders. The transaction is subject to approval at an extraordinary general meeting Enzymatica will give notice of.

What does the transaction entail with respect to your patent protection for ColdZyme?

The patent prevents others from developing or selling products based on the enzyme from cod and expires at the end of 2020, i.e. in five years. The patent covers Europe and certain key markets outside of the EU, including the largest markets for OTC products – Oceania, Canada, Russia, Poland, China, India and Mexico.

What is your opinion on the fact that the patent does not cover the US and Japan, the largest markets for medical equipment/OTC products?

Given that Zymetech is the only producer of the relevant deep-sea enzymes, the merger also gives Enzymatica global control over the raw material, which substantially slows down competition in important countries where Enzymatica does not have full patent protection, such as the US. Enzymatica has a technological lead of several years across the globe. In October 2015, a new patent application was published for a recombinant trypsin, which we expect will supplement the patent for the natural trypsin when it expires. This patent will cover the US as well. We have also filed several patent applications to protect our technology.

What role will Zymetech have in Enzymatica?

Researchers and product developers from Zymetech will be added to the research and development department while continuing to work in Iceland. All production and refinement of the enzyme raw material will also remain in Iceland, as well as several other functions. Zymetech's founder will become the largest single shareholder of Enzymatica and will initially be offered two board posts and a position on the nominations committee.

Does Zymetech have any agreements with distributors on the international market for sales of trypsin and for their own spray?

Zymetech mainly has agreements for dermatology products in Germany, the UK and an Asian market.

How much sales do these agreements generate for Zymetech?

SEK 3-5 million per year.

Why does Enzymatica want to conduct a preemptive rights issue of SEK 60 million?

The capital contributed from the issue will bolster the company’s financial position and we believe that this will enable faster geographic expansion. The purpose is to enable us to pursue commercial opportunities more aggressively and thus foster a long-term increase in the sales of cold product ColdZyme.

The capital contribution will facilitate preparation for the regulatory approval in the US, Asia, Australia and other regions outside of Europe, continuing diversification of the product portfolio and solid sales support for distribution partners in the form of a small internal marketing structure, including key personnel such as international product managers.

What does it mean that the new share issue has preemptive rights for existing shareholders?

It means that those who are registered as shareholders on the record date will receive warrants in proportion to their shareholdings. These shareholders are then given the opportunity to subscribe for new shares before others. The preemptive rights are represented by the warrants allotted.

Why is Enzymatica requesting a mandate to be able to conduct a private placement of SEK 40 million?

The reason for the extended mandate for a private placement is to take advantage of future opportunities to bring in strong long-term owners and provide additional financing for the company's growth strategy.

You raised SEK 80 million just over two years ago, how have these funds been used?

We launched ColdZyme on five new markets: Norway, Denmark, the UK, Finland and Spain in January 2016. As part of these product launch efforts, we ensured that the product is in compliance with each country's legal and regulatory requirements, e.g. by supplementing the documentation forming the basis for the product’s registration and making adaptations to advertising and marketing materials. Intensified quality efforts within the company have been underway since one year ago. These efforts are necessary to reach more geographic markets. We have also expanded our organizational structure so it can cope with the expansion, doubling our workforce to 15 one year ago. In addition, we have continued to invest in production and development projects related to ColdZyme.

Read more »
Media no image

Questions and Answers – regarding the ASA decision, for marketing- and web material of ColdZyme in the UK

News   •   Jan 27, 2016 15:51 GMT

1.Why has the ASA ruled on the content of your ColdZyme ads and Boots’ website? 

ASA is acting on two complaints about claims we have made in a poster and that were made about the product on Boots’ website back in 2014, we have already taken the appropriate corrective action, changing the claims. ASA has the responsibility to see that advertising rules in the CAP code (The UK Code of Non-broadcast Advertising, Sales Promotion and Direct Marketing) in UK are followed and therefore looked into these complaints.

2.What scientific data do you have to support the claims in the ads?

We have one placebo-controlled study and a few open label studies. These studies support the following claims; ColdZyme can reduce the viral load and can help reduce the number of sick-days suffered with a common cold, when used prophylactically.We feel that these are reasonable claims, and these have been adjusted to comply with the ASA decision.

3.You state in the ads “could prevent or shorten the common cold at the first signs” – what data do you have to support this statement?

Following the ASA decision we have already adjusted our claim in web and marketing material to adhere to the decision. ColdZyme is unique since it acts on the cold virus itself, as opposed to addressing symptoms when already ill. ColdZyme can reduce the viral load in the throat and can help reduce the number of sick-days of a common cold, when used prophylactically.

4.Do you intend to follow and comply with the ASA decision? And if yes, in what way?

We have considered the ASA decision, and have already taken the appropriate corrective action. The poster is not in use, and the website has been amended accordingly.

5.Don’t you think that this type of marketing and information will be harmful to the trust of your product and company?

We strongly believe that our current marketing is supported by reliable and relevant clinical data. Bear in mind that we also have an obligation to our customers to guide them in how to use ColdZyme in the best way. According to good clinical and marketing practice, we are constantly increasing our knowledge around the product by collecting more clinical data as well as post-marketing information for the benefit of the user.

6.How have you communicated with Boots and Lloyds?

The ASA decision has been shared with Boots and Lloyds and corrective action has been taken to adhere to ASA’s decision.

Read more »
Dnmvjhem31oj9mzppr7m

Fredrik Lindberg appointed CEO of Enzymatica

Press Releases   •   Nov 17, 2014 10:00 GMT

Media no image

Launch in Denmark expands ColdZyme® to all of Scandinavia

Press Releases   •   Oct 13, 2014 06:30 GMT

Enzymatica, which develops and sells medical device products based on an enzyme from deep-sea cod, has signed agreements with the pharmacy chain Pharma+ and the wellness chain Matas in Denmark to sell ColdZyme® against common colds. From November this year, ColdZyme will be available on the Danish market, and thus in all of Scandinavia.

"According to plan, we are expanding to our neighboring countries using our own sales organization, building a platform of close relationships with the pharmacy and wellness market throughout Scandinavia. The expanded geographic presence sets the scene for continued growth and further geographic expansion. A strong domestic market position supports successful international distribution later on", says Christian W. Jansson, CEO, Enzymatica.

ColdZyme will be sold in Denmark through Pharma+, one of the dominant chains with pharmacies in metropolitan areas, as well as through the wellness chain Matas’ approximately 300 stores throughout Denmark. In a similar way as in Sweden and Norway, the pharmacies will be trained and supported by Enzymatica’s own local sales organization. The product launch will begin in late October and continue throughout the cold season. Enzymatica will conduct a widespread launch campaign to achieve maximum coverage to the Danish population.

"I am delighted that we have ColdZyme in the Danish pharmaceutical market. The product brings something really new in the cold segment by acting directly on the cause of the common cold”, said Jorgen Moestrup, Chairman of Pharma+.

The common cold is one of the most common infectious diseases. Enzymatica estimates that the total value of the non-prescription cold and flu market in Denmark amounts to approximately SEK 375 million.

For more information, please contact:
Christian W Jansson, CEO Enzymatica AB
Phone: +46 706 37 12 58. Email: ir@enzymatica.se

Tina Dackemark Lawesson, Senior Communications Officer Enzymatica AB
Phone: +46 46 286 31 00. Email: tina.lawesson@enzymatica.se

About ColdZyme 

ColdZyme ® Mouth spray reduces the risk of getting a cold or shortens the period of illness in the early stages of a cold infection if you are already affected. ColdZyme exerts its effect by creating a protective barrier enzyme in the lining of the mouth and throat. The barrier reduces the viruses' ability to attach to cells in the oral mucosa and cause disease. The product has been on sale via pharmacies and health specialist stores in Sweden since 2013. In 2014 the product expanded to pharmacies in Norway and the Boots pharmacy chain in the UK. For more information, please visit www.coldzyme.com.

About Enzymatica AB (publ)

Enzymatica AB (publ) develops and sells medical technology products based on an enzyme from deep-sea cod. They include medical devices for upper respiratory infections and oral health, and veterinary products in oral health and dermatology. The medical portfolio includes ColdZyme® against common colds. The company is headquartered in Lund, Sweden, and is listed on Aktietorget. For more information, please visit www.enzymatica.com.

Read more »
Media no image

Enzymatica receives first order for veterinary products from its partner in North America

Press Releases   •   Sep 26, 2014 06:30 GMT

Enzymatica, which develops and sells medical products based on an enzyme from deep-sea cod, is announcing today that its partner Adartis Animal Health has placed a first order for the veterinary products launched in the United States and Canada in July. The order includes KalvatinTM products to a value of about SEK 3 million and is expected to cover market needs for the next six to twelve months. The first part delivery will be made in the fourth quarter of 2014 and is expected to have a positive impact on earnings of more than SEK 1 million.

“Our partner has recently started the work of introduction and the market is in the build-up phase. We look forward to following the activities in the market during the coming fall and winter. Veterinary products broaden our product portfolio and provide a long term opportunity to grow in a new segment,” says Christian W. Jansson, acting CEO of Enzymatica.

The KalvatinTM products are marketed and sold in North America by Enzymatica’s partner Adartis Animal Health. The products target companion animal veterinary clinics. In the United States and Canada, there are about 44,000 veterinary clinics.*

Kalvatin Dermal and Kalvatin Dental are enzyme-based products for treating skin and gum infections, primarily in dogs and cats. The spray/gel creates a protective surface barrier that prevents bacteria from causing infection. Development has been on the same technology platform as Enzymatica’s common cold product ColdZyme®.

The Kalvatin products were launched at the AVMA Annual Convention in Denver, USA on July 25-29, 2014.

For more information, please contact:
Christian W Jansson, acting CEO Enzymatica AB
Phone: +46 706 37 12 58. E-mail: ir@enzymatica.se

Tina Dackemark Lawesson, Senior Communications Officer Enzymatica AB
Phone: +46 46 286 31 00. E-mail: tina.lawesson@enzymatica.se

For more information about Adartis and the KalvatinTM products, please visit:
www.adartisanimalhealth.com www.kalvatin.com

* American Pet Products Associations website 2014.

About Enzymatica AB (publ)

Enzymatica AB (publ) develops and sells medical technology products based on an enzyme from deep-sea cod. They include medical devices for upper respiratory infections and oral health, and veterinary products in oral health and dermatology. The medical portfolio includes ColdZyme® against common colds. The company is headquartered in Lund, Sweden, and is listed on Aktietorget. For more information, please visit www.enzymatica.com.

Read more »
Media no image

New Chairman of the Board at Enzymatica

Press Releases   •   Sep 11, 2014 08:09 GMT

While Christian W. Jansson has taken the position as acting CEO in Enzymatica, he has consequently stepped down as Chairman of the Board. Board member Fredrik Lindberg has been appointed new Chairman of Enzymatica.

Fredrik Lindberg, member of Enzymatica’s Board since 2012, is the Chief Scientific Officer and co-founder of Bone Support AB. Fredrik is a Doctor of Medicine (Ph.D), and has extensive experience in the medical device industry and growth companies with international operations.

For more information, please contact:
Christian W. Jansson, acting CEO Enzymatica AB
Phone: +46 706 37 12 58. E-mail: ir@enzymatica.se

Tina Dackemark Lawesson, Senior Communications Officer Enzymatica AB
Phone: +46 286 31 00. E-mail: tina.lawesson@enzymatica.se

About Enzymatica AB (publ)

Enzymatica AB (publ) develops and sells medical technology products based on an enzyme from deep-sea cod. Our development includes medical devices in upper respiratory infections and oral health, and veterinary products in oral health and dermatology. The launched medical portfolio includes ColdZyme® against common colds. It is headquartered in Lund, Sweden, and is listed on Aktietorget. For more information, please visit www.enzymatica.com.


Read more »
Media no image

Enzymatica appoints acting CEO

Press Releases   •   Sep 09, 2014 09:44 GMT

Enzymatica’s Chairman Christian W. Jansson is today taking over as acting CEO of Enzymatica until a permanent successor has been recruited.

Michael Edelborg Christensen has decided to leave Enzymatica after five years in the company. The process of recruiting a new CEO will begin immediately.

- Enzymatica thank Michael for a fantastic job during his years in the company. His dedication and drive have been very important for the company's positive development. The Board and CEO have different views on strategic issues and Michael therefore chooses to leave the company. We respect his decision and wish him well in the future. The company's expansion plans to invest in more markets and new products remain unchanged, says Christian W. Jansson.

Christian W. Jansson has served as the company's Chairman of the Board since May 2013 and has good insight in the company. Christian has extensive experience in both small and large growth companies, and retail, including from his time as President and CEO of KappAhl AB and Ellos AB. He serves on the board of several companies, including Apoteket AB, EuroPrice AS, KappAhl AB and Vivoline Medical AB. In Enzymatica he remains as Chairman.


For more information, please contact:
Christian W Jansson, Chairman of the Board and acting CEO Enzymatica AB
Phone: +46 706 37 12 58. E-mail: ir@enzymatica.se

Tina Dackemark Lawesson, Senior Communications Officer Enzymatica AB
Phone: +46 286 31 00. E-mail: tina.lawesson@enzymatica.se

About Enzymatica AB (publ)

Enzymatica AB (publ) develops and sells medical technology products based on an enzyme from deep-sea cod. Our development includes medical devices in upper respiratory infections and oral health, and veterinary products in oral health and dermatology. The launched medical portfolio includes ColdZyme® against common colds. It is headquartered in Lund, Sweden, and is listed on Aktietorget. For more information, please visit www.enzymatica.com.

Read more »
Media no image

Enzymaticas veterinary products launched at the AVMA Annual Convention in Denver, USA

Press Releases   •   Jul 24, 2014 06:35 GMT

Enzymatica, which develops and sells products based on enzyme from deep-sea cod, today announces that its new veterinary products will be presented at the AVMA Annual Convention in Denver, USA on July 25-29 2014. The launch is through Enzymatica’s U.S. distributor Adartis Animal Health.

The products, Kalvatin® Dermal and Kalvatin® Dental, are enzyme-based products against skin and gum infections. The products’ target audience is veterinary clinics primarily for dogs, cats and horses.

- The Kalvatin products are an innovative addition to our product offering and part of our focus on international markets. We look forward to following our distributor's activities in the market during the coming fall and winter. Marketing has just started and is still in the development phase, says Michael Edelborg Christensen, CEO of Enzymatica.

The development of veterinary products has been on the same technology platform used in Enzymaticas common cold product ColdZyme®. As animal pathogens and human pathogens are similar, the corresponding barrier-building system developed for human indications can also be used to treat animals.

Sales to veterinary clinics in North America will be through the U.S. distributor Adartis Animal Health, who is also responsible for product marketing activities. To support the distributor, Enzymatica has established a subsidiary, Enzymatica North America Inc.

U.S. is the biggest market for veterinary products. In the U.S., about two-thirds of the households have pets, where dogs and cats are the most common animals. The number of veterinary clinics amounts to approximately 44, 000.*

The organization behind the exhibition is the American Veterinary Medical Association (AVMA) with approximately 85,000 veterinarians and veterinary students as members.

For more information, please contact:
Michael Edelborg Christensen, CEO Enzymatica AB (publ) 
Phone: +46 768 14 41 66. E-mail: michael.christensen@enzymatica.se

For more information about Adartis Animal Health and the Kalvatin® products, please visit: www.adartisanimalhealth.com www.kalvatin.com

* American Pet Products Associations website 2014.

About Enzymatica AB (publ)
Enzymatica AB (publ) develops and sells medical technology products based on an enzyme from deep-sea cod. Our development includes medical devices in upper respiratory infections and oral health, and veterinary products in oral health and dermatology. Its launched medical portfolio includes ColdZyme® CE Mouth spray for colds, available at the Swedish pharmacy market since 2013. It is headquartered in Lund, Sweden and is listed on Aktietorget. For more information, please visit www.enzymatica.se. 

Read more »

Contacts 2 contacts

  • Press Contact
  • Senior Communication Officer
  • Corporate Communications
  • jorgen.rexo@enzymatica.com
  • +46(0) 708 19 22 82
  • +46 46 286 31 00

  • Press Contact
  • EVP Marketing & Operations
  • ulf.blom@enzymatica.se
  • 0703777328
  • 0462863100

About Enzymatica AB (publ)

Welcome to Enzymatica AB

Enzymatica is a publicly traded biotechnology company focused on research, development and sales of innovative enzyme-based products. Enzymaticas products is based primarily on a cold adapted enzyme that can be used to create active protective barrier against pathogens. In close collaboration with clinical researchers, the company develops new products for upper respiratory infections, oral infections and inflammations, in dermatology and vetrinary applications.Enzymatica develops products in different market segments to create better customer value , broad recognition and market presence. The sales goes via our own organisation in Scandinavia and through strategic distribution and cooperation agreements for selected geographic markets and countries.